HRP20180189T1 - Kristalna faza (3s,3s')-4,4'-disulfandiilbis(3-aminobutan-1-sulfonske kiseline) s l-lizinom - Google Patents

Kristalna faza (3s,3s')-4,4'-disulfandiilbis(3-aminobutan-1-sulfonske kiseline) s l-lizinom Download PDF

Info

Publication number
HRP20180189T1
HRP20180189T1 HRP20180189TT HRP20180189T HRP20180189T1 HR P20180189 T1 HRP20180189 T1 HR P20180189T1 HR P20180189T T HRP20180189T T HR P20180189TT HR P20180189 T HRP20180189 T HR P20180189T HR P20180189 T1 HRP20180189 T1 HR P20180189T1
Authority
HR
Croatia
Prior art keywords
lysine
absd
crystalline form
carried out
crystalline
Prior art date
Application number
HRP20180189TT
Other languages
English (en)
Croatian (hr)
Inventor
Fabrice Balavoine
Jean-Marie Schneider
Gérard Coquerel
Nicolas Couvrat
Original Assignee
Quantum Genomics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quantum Genomics filed Critical Quantum Genomics
Publication of HRP20180189T1 publication Critical patent/HRP20180189T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/26Separation; Purification; Stabilisation; Use of additives
    • C07C319/28Separation; Purification
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38Separation; Purification; Stabilisation; Use of additives
    • C07C227/40Separation; Purification
    • C07C227/42Crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/66Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfo, esterified sulfo or halosulfonyl groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20180189TT 2012-10-22 2013-10-22 Kristalna faza (3s,3s')-4,4'-disulfandiilbis(3-aminobutan-1-sulfonske kiseline) s l-lizinom HRP20180189T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306307.5A EP2722327A1 (en) 2012-10-22 2012-10-22 Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
PCT/EP2013/072028 WO2014064077A1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s.3s') 4,4'-disulfanediylbis(3-aminobutane 1 -sulfonic acid) with l-lysine
EP13779603.3A EP2909169B1 (en) 2012-10-22 2013-10-22 Crystalline phase of (3s,3s') 4,4'-disulfanediylbis(3-aminobutane 1-sulfonic acid) with l-lysine

Publications (1)

Publication Number Publication Date
HRP20180189T1 true HRP20180189T1 (hr) 2018-04-20

Family

ID=47278723

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180189TT HRP20180189T1 (hr) 2012-10-22 2013-10-22 Kristalna faza (3s,3s')-4,4'-disulfandiilbis(3-aminobutan-1-sulfonske kiseline) s l-lizinom

Country Status (30)

Country Link
US (2) US9278921B2 (https=)
EP (2) EP2722327A1 (https=)
JP (1) JP6317358B2 (https=)
KR (1) KR102103407B1 (https=)
CN (1) CN104768927B (https=)
AR (1) AR093070A1 (https=)
AU (1) AU2013336738B2 (https=)
BR (1) BR112015008931B1 (https=)
CA (1) CA2884914C (https=)
CY (1) CY1119913T1 (https=)
DK (1) DK2909169T3 (https=)
EA (1) EA024460B1 (https=)
ES (1) ES2658413T3 (https=)
HR (1) HRP20180189T1 (https=)
HU (1) HUE036037T2 (https=)
IL (1) IL237733B (https=)
IN (1) IN2015DN02807A (https=)
LT (1) LT2909169T (https=)
ME (1) ME02955B (https=)
MX (1) MX353693B (https=)
NO (1) NO2909169T3 (https=)
NZ (1) NZ706070A (https=)
PL (1) PL2909169T3 (https=)
PT (1) PT2909169T (https=)
RS (1) RS56896B1 (https=)
SI (1) SI2909169T1 (https=)
SM (1) SMT201800086T1 (https=)
TW (1) TWI643842B (https=)
WO (1) WO2014064077A1 (https=)
ZA (1) ZA201503574B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103951562B (zh) * 2014-05-09 2016-04-20 四川九章生物化工科技发展有限公司 一种绿原酸晶型及其制备方法
WO2022225712A1 (en) * 2021-04-22 2022-10-27 Teva Pharmaceuticals International Gmbh Solid state forms of firibastat and processes for preparation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2309336T3 (es) * 2002-07-16 2008-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Derivados de 4,4-ditiobis-(3-aminobutano-1-sulfanatos) nuevos y composiciones que los contienen.
FR2858617A1 (fr) * 2003-08-06 2005-02-11 Inst Nat Sante Rech Med Derives de 4',4'-dithiobis-(3-aminobutane-1-sulfonate-1- sulfonates) nouveaux et compositions les contenant
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2439192A1 (en) 2010-10-07 2012-04-11 Quantum Genomics Method for the preparation of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid)
US9447050B2 (en) * 2011-04-05 2016-09-20 The Translational Genomics Research Institute Solid forms of curcumin

Also Published As

Publication number Publication date
CA2884914A1 (en) 2014-05-01
ES2658413T3 (es) 2018-03-09
CA2884914C (en) 2021-01-05
US20150284325A1 (en) 2015-10-08
MX2015005059A (es) 2015-11-23
CY1119913T1 (el) 2018-06-27
TW201418202A (zh) 2014-05-16
BR112015008931A2 (pt) 2017-07-04
WO2014064077A1 (en) 2014-05-01
HK1212321A1 (en) 2016-06-10
AU2013336738A1 (en) 2015-04-09
BR112015008931B1 (pt) 2021-05-18
RS56896B1 (sr) 2018-04-30
ZA201503574B (en) 2016-01-27
EA201500438A1 (ru) 2015-09-30
CN104768927B (zh) 2017-06-09
JP2015536316A (ja) 2015-12-21
AU2013336738B2 (en) 2017-05-18
KR102103407B1 (ko) 2020-04-22
KR20150072454A (ko) 2015-06-29
JP6317358B2 (ja) 2018-04-25
PL2909169T3 (pl) 2018-07-31
PT2909169T (pt) 2018-02-26
EP2909169A1 (en) 2015-08-26
NO2909169T3 (https=) 2018-06-02
MX353693B (es) 2018-01-24
IL237733B (en) 2019-03-31
DK2909169T3 (en) 2018-02-26
NZ706070A (en) 2018-11-30
US9487477B2 (en) 2016-11-08
SI2909169T1 (en) 2018-04-30
LT2909169T (lt) 2018-04-25
US9278921B2 (en) 2016-03-08
ME02955B (me) 2018-07-20
HUE036037T2 (hu) 2018-06-28
AR093070A1 (es) 2015-05-13
SMT201800086T1 (it) 2018-05-02
EA024460B1 (ru) 2016-09-30
IN2015DN02807A (https=) 2015-09-11
EP2722327A1 (en) 2014-04-23
US20160221940A1 (en) 2016-08-04
CN104768927A (zh) 2015-07-08
EP2909169B1 (en) 2018-01-03
TWI643842B (zh) 2018-12-11

Similar Documents

Publication Publication Date Title
FI3351539T3 (fi) Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä
HRP20171201T1 (hr) Postupak kristalizacije i biodostupnost
RU2017117413A (ru) Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
WO2013100176A3 (en) Method of producing a low odor glycerin derivative-modified silicone or a composition comprising the same
ATE482961T1 (de) Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung
WO2012017166A3 (fr) Traitement d&#39;une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
PH12013500261A1 (en) Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
MX2016001096A (es) Sales de dasatinib en forma amorfa.
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2011126245A3 (en) Novel method of preparing vanadosilicate molecular sieve and novel vanadosilicate molecular sieve
AR109729A1 (es) Método para producir la forma cristalina de modificación a de calcobutrol
EP2576576A4 (en) HETEROCYCLYL-PYRIDINYL BASE PHOSPHONIC ACID, PHARMACEUTICALLY ALLOWED SALT, COMPOSITION, AND METHOD OF USE THEREOF
JO3208B1 (ar) عملية من داي هيدرات-نصف هيدرات لإنتاج حمض فسفوري
EA201490578A1 (ru) Полиморфная форма питавастатина кальция
EA201491374A1 (ru) НОВЫЕ ФОРМЫ И СОЛИ ДИГИДРОПИРРОЛ[1,2-c]ИМИДАЗОЛИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ АЛЬДОСТЕРОНСИНТАЗЫ ИЛИ АРОМАТАЗЫ
HRP20180189T1 (hr) Kristalna faza (3s,3s&#39;)-4,4&#39;-disulfandiilbis(3-aminobutan-1-sulfonske kiseline) s l-lizinom
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
WO2015011120A3 (en) Salts of dasatinib in crystalline form
FR3053336B1 (fr) Procede de preparation de l&#39;acide 2,5-furane dicarboxylique (fdca) a partir de derives de pentoses
EP2651221A4 (en) PROCESS FOR THE PREPARATION AND USE OF BRASSINOSTEROIDS TO PROMOTE GROWTH, REPAIR AND CARE OF SKELETAL MUSCLES AND SKIN
FR2985511B1 (fr) Forme cristalline delta du sel d&#39;arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
MX357129B (es) Precipitacion de zinc de la solucion.
FR3053364B1 (fr) Procede de recuperation de platine, par voie electrochimique, a partir d&#39;un materiau dans lequel il est contenu
UA106580C2 (uk) Фармацевтично прийнятні солі тимодепресину і спосіб їх виробництва
IT1399923B1 (it) Procedimento di preparazione di sali dell&#39;acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono